Lilly Oncology to Unveil More Than 50 Studies at ASCO 2008
May 01 2008 - 9:00AM
PR Newswire (US)
ALIMTA Lung Cancer Study Highlighting Key Histology Findings to Be
Included in May 15 ASCO Live, Online Presscast INDIANAPOLIS, May 1
/PRNewswire-FirstCall/ -- Eli Lilly and Company will unveil data
from more than 50 studies at the 44th Annual Meeting of the
American Society of Clinical Oncology (ASCO) in Chicago, Ill. from
May 30 to June 3, 2008. The company will present the latest
research findings on ALIMTA(R) (pemetrexed for injection),
GEMZAR(R) (gemcitabine HCl for injection), and enzastaurin, an
investigational, oral, targeted therapy. The majority of the
studies being presented are findings that support Lilly's
leadership in thoracic cancer research. Of note is a pivotal Phase
III study (ASCO Abstract # 8011) that demonstrated a key
correlation between lung cancer histology (tissue type), treatment
choice and patient outcome. It will be one of the studies featured
on Thursday, May 15 in ASCO's live online presscast. The virtual
press event will be the first time ASCO has selected researchers to
present key abstracts prior to its annual meeting. "Improved
patient outcomes via tailored therapy continues to be our focus and
this year's ASCO is no exception," said Richard Gaynor, M.D., Lilly
vice president, cancer research and global oncology platform
leader. "With Lilly studies focusing on thoracic and breast cancer,
among others, this meeting will continue to show our commitment to
answering the unmet needs of cancer care." Key Pemetrexed Abstracts
for ASCO 2008: -- Abstract # 8011: June 2, 2008; 3:00 p.m. --
Maintenance pemetrexed plus best supportive care (BSC) versus
placebo plus BSC: A phase III study -- This study will be featured
during ASCO presscast on May 15 -- Abstract # 8096: June 1, 2008;
2:00 p.m. -- Comparison of patient outcomes stratified by histology
among pemetrexed-treated patients with stage IIIB/IV NSCLC in two
Phase II trials -- Abstract # 8097: June 1, 2008; 2:00 p.m. --
Resource utilization by non-small cell lung cancer histology:
Results from the randomized, phase III trial of
pemetrexed/cisplatin versus gemcitabine/cisplatin For more
information on Lilly Oncology agents, including full prescribing
information, please visit http://www.lillyoncology.com/ . (Logo:
http://www.newscom.com/cgi-bin/prnh/20080416/CLW066LOGO )
http://www.newscom.com/cgi-bin/prnh/20080416/CLW066LOGO DATASOURCE:
Eli Lilly and Company CONTACT: Amy Sousa of Eli Lilly and Company,
+1-317-276-8478, Mobile: +1-317-997-1481, or Neil Hochman of CPR
Worldwide, +1-212-453-2067, Mobile: +1-516-784-9089
Copyright